Aakash Desai: Sacituzumab govitecan continues to show promise as a 2-line treatment for extensive-stage SCLC
Aakash Desai, Assistant Professor at UAB O’Neal Comprehensive Cancer Center, shared on LinkedIn:
“Sacituzumab govitecan (SG) continues to show promise as a second-line treatment for extensive-stage small-cell lung cancer (ES-SCLC).
The phase 2 TROPiCS-03 study in JTO highlights:
Objective Response Rate (ORR): 41.9%
Median Progression-Free Survival (PFS): 4.4 months
Median Overall Survival (OS): 13.6 months
G3 or more TEAEs: 74%
These results were consistent across both platinum-sensitive and platinum-resistant patients.
This adds to the growing evidence for SG as a potential option in the challenging ES-SCLC treatment landscape.”
Authors: Anne C. Chiang, Andrés Cervantes, Sunil Babu, Erika Hamilton, Shu Fen Wong, Andrea Tazbirkova, Ivana Gabriela Sullivan, Cédric van Marcke, Antoine Italiano, Jilpa Patel, Sabeen Mekan, Tia Wu, Saiama N. Waqar.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023